Valsartan

Evidence Level: L4

Predicted Indications: 10

Valsartan
Valsartan: From Hypertension to Malignant Hypertensive Renal Disease

## Pharmacist Assessment Report

Valsartan: From Hypertension to Malignant Hypertensive Renal Disease

One-Sentence Summary

Valsartan is an angiotensin II receptor blocker originally used to treat hypertension. The TxGNN model predicts it may be effective for malignant hypertensive renal disease, but no clinical trials and only 1 indirect publication (a preclinical study of a different drug) currently support this direction.

Quick Overview

Item	Content
Original Indication	Hypertension (hypertensive disorder)
Predicted New Indication	Malignant hypertensive renal disease
TxGNN Prediction Score	99.97%
Evidence Level	L4
Singapore Market Status	✓ Marketed
Number of Registrations	20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, valsartan belongs to the angiotensin II type 1 (AT1) receptor blocker class. Its efficacy in hypertension is established, and it is also known to lower blood pressure and protect the kidney.

Malignant hypertension and its kidney injury are strongly driven by the renin-angiotensin system. Blocking the AT1 receptor is therefore mechanistically on target. The same reasoning applies to the second-ranked prediction, malignant renovascular hypertension, where preclinical work (PMID 11560862) suggests AT1 blockade can prevent lethal malignant hypertension in an animal model.

However, the only paper retrieved for the top prediction (PMID 24368192) studies avosentan, an endothelin antagonist, in rats. It does not test valsartan. The prediction is therefore biologically plausible but not directly supported by valsartan-specific data.

Other predictions in the list are weaker. Chronic pulmonary heart disease (rank 6) has some indirect clinical data, mostly on the sacubitril/valsartan combination in heart failure. Pulmonary hypertension, Braddock syndrome, Prinzmetal angina, and the remaining predictions rest on prediction alone or on off-topic literature.

Clinical Trial Evidence

Currently no related clinical trials registered for malignant hypertensive renal disease.

For reference, the only trial linked to any of the top-ranked predictions is for chronic pulmonary heart disease (rank 6), and it is only loosely relevant:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02966665	Phase 1	Recruiting	420	Exercise rehabilitation and vascular function in hypertension; does not directly test valsartan

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24368192	2014	Preclinical	Pharmacological Research	Avosentan (not valsartan) protected against hypertensive nephropathy in transgenic rats at doses that did not cause fluid retention

Related indirect evidence for the second-ranked prediction, malignant renovascular hypertension:

PMID	Year	Type	Journal	Key Findings
11560862	2001	Preclinical	Circulation	AT1 receptor blockade prevented lethal malignant hypertension in an animal model, linked to reduced kidney inflammation

Singapore Market Information

All 20 registrations are valid single-ingredient licences in oral film-coated tablet form. The approved indication text was not available for these licences. Five main authorizations:

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN11555P	DIOVAN TABLET 80 mg	Film-coated tablet	Not available
SIN11554P	DIOVAN TABLET 160 mg	Film-coated tablet	Not available
SIN14139P	Valsartan Sandoz film coated tablet 80mg	Film-coated tablet	Not available
SIN14140P	Valsartan Sandoz film coated tablet 160mg	Film-coated tablet	Not available
SIN12011P	CO-DIOVAN 160/25 TABLET	Film-coated tablet	Not available

Safety Considerations

Contraindication-related conditions (from the knowledge graph, not label text): Conditions linked to valsartan as cautions include angioedema (including hereditary and RAAS-blocker-induced forms), liver disease and liver failure, hepatic encephalopathy, impaired renal function, anuria, renal artery obstruction, hypotensive disorder, diabetes mellitus and diabetic ketoacidosis, potassium deficiency disease, gout, hypercalcemia, hyperparathyroidism, neutropenia and agranulocytosis, systemic lupus erythematosus, pancreatitis, gallbladder disease, and neonatal jaundice. Of particular relevance to the predicted use, renal artery obstruction and impaired renal function are listed, so kidney safety needs careful evaluation.
Drug Interactions: 100 interactions were recorded. The main ones include:
- Major: potassium chloride and potassium bicarbonate (risk of raised potassium).
- Moderate: many insulin products, exenatide, hydrocortisone, eluxadoline, and polyethylene glycol 3350 with electrolytes.

Please also refer to the package insert for the full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is very high (99.97%), and blocking the renin-angiotensin system is biologically sensible for malignant hypertensive kidney injury. However, no clinical trials exist, and the only retrieved paper tests a different drug in animals. Evidence is limited to L4 (mechanistic and preclinical). Valsartan's kidney-related cautions also require a safety evaluation.

To proceed, the following is needed:

Valsartan-specific preclinical or clinical data in malignant hypertensive nephropathy
Detailed mechanism of action data
Package insert warnings and contraindications from the HSA, to enable safety screening
Approved indication text for the Singapore licences
A renal safety assessment (renal artery stenosis, impaired renal function, hyperkalaemia risk)
Consideration of chronic pulmonary heart disease as a secondary research question, since it has the most indirect clinical data (largely from sacubitril/valsartan)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.